1![European Fund for Strategic Investments (EFSI) - Equity signatures as of European Fund for Strategic Investments (EFSI) - Equity signatures as of](https://www.pdfsearch.io/img/94002cf50b78ffb88d53dbe019e95150.jpg) | Add to Reading ListSource URL: www.eif.europa.euLanguage: English - Date: 2016-08-16 02:59:53
|
---|
2![SVB PowerPoint Presentation SVB PowerPoint Presentation](https://www.pdfsearch.io/img/98baf7fd7dfbacef8b725d6b73f87188.jpg) | Add to Reading ListSource URL: www.svb.comLanguage: English - Date: 2016-01-11 09:18:50
|
---|
3![_____________________________________________________________________________October 2016 Brussels, Belgium FOUNDATION IN FINANCE & ADMINISTRATION _____________________________________________________________________________October 2016 Brussels, Belgium FOUNDATION IN FINANCE & ADMINISTRATION](https://www.pdfsearch.io/img/ca0efb0ba4e603a8f5a60a8ba21cbc8d.jpg) | Add to Reading ListSource URL: www.investeurope.euLanguage: English - Date: 2016-03-15 04:45:39
|
---|
4![Inotrem Financing Inotrem Financing](https://www.pdfsearch.io/img/2a2bffc0c43c5de20787be1c6196f47e.jpg) | Add to Reading ListSource URL: www.biomedvc.comLanguage: English - Date: 2014-08-28 07:53:12
|
---|
5![Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners Lausanne, Switzerland, September 29th, 2015. Asceneuron SA, an emerging leader in the development of first-in-class small molecules Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners Lausanne, Switzerland, September 29th, 2015. Asceneuron SA, an emerging leader in the development of first-in-class small molecules](https://www.pdfsearch.io/img/27fc591f28abc1ca1cfe39d7fd9717dc.jpg) | Add to Reading ListSource URL: www.asceneuron.comLanguage: English - Date: 2015-09-29 04:05:37
|
---|
6![](https://www.pdfsearch.io/img/db24042a4b291ed7c82eb400880e3aa9.jpg) | Add to Reading ListSource URL: sofinnova.comLanguage: English - Date: 2015-04-02 17:04:19
|
---|
7![](https://www.pdfsearch.io/img/dc57848e2c89aeb59901c7da9b1c9b7b.jpg) | Add to Reading ListSource URL: sofinnova.comLanguage: English - Date: 2013-03-26 11:32:00
|
---|
8![](https://www.pdfsearch.io/img/d9967a29c379ab01110368f34cd0bbde.jpg) | Add to Reading ListSource URL: sofinnova.comLanguage: English - Date: 2015-02-26 19:12:01
|
---|
9![Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa® (icosapent ethyl) in China BEDMINSTER, N.J., DUBLIN, Ireland, and MACAO S.A.R, People’s Republic of China, February 26, Amarin Co Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa® (icosapent ethyl) in China BEDMINSTER, N.J., DUBLIN, Ireland, and MACAO S.A.R, People’s Republic of China, February 26, Amarin Co](https://www.pdfsearch.io/img/961b54648604398a16498d9ae066d92c.jpg) | Add to Reading ListSource URL: www.sofinnova.comLanguage: English - Date: 2015-02-26 19:12:01
|
---|
10![ATyr Pharma Brings Venture, Crossover Investors Into $76M Series E Financing Brian Gormley April 01, 2015 After moving its first drug based on its Physiocrine technology into clinical studies, aTyr Pharma Inc . has raise ATyr Pharma Brings Venture, Crossover Investors Into $76M Series E Financing Brian Gormley April 01, 2015 After moving its first drug based on its Physiocrine technology into clinical studies, aTyr Pharma Inc . has raise](https://www.pdfsearch.io/img/f3dc4a35e29ca930a47b7b5221b98fdd.jpg) | Add to Reading ListSource URL: www.sofinnova.comLanguage: English |
---|